Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III ICT-107 plus maintenance temozolomide in newly diagnosed glioblastoma
2015-002685-23Phase 3Terminated
- Sponsor
- EOM Pharmaceutical Holdings, Inc.
- Start
- Feb 2016
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in glioblastoma (GBM) comparing ICT-107 + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Overall survival. Started Feb 2016; status: terminated.
02
Drugs
ict-107
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2015-002685-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002685-23.